160 related articles for article (PubMed ID: 37106808)
1. Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib.
Car I; Dittmann A; Klobučar M; Grbčić P; Kraljević Pavelić S; Sedić M
Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106808
[TBL] [Abstract][Full Text] [Related]
2. Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro.
Car I; Dittmann A; Vasieva O; Bočkor L; Grbčić P; Piteša N; Klobučar M; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629086
[TBL] [Abstract][Full Text] [Related]
3. Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib.
Grbčić P; Fučkar Čupić D; Gamberi T; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201061
[TBL] [Abstract][Full Text] [Related]
4. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
Beck D; Niessner H; Smalley KS; Flaherty K; Paraiso KH; Busch C; Sinnberg T; Vasseur S; Iovanna JL; Drießen S; Stork B; Wesselborg S; Schaller M; Biedermann T; Bauer J; Lasithiotakis K; Weide B; Eberle J; Schittek B; Schadendorf D; Garbe C; Kulms D; Meier F
Sci Signal; 2013 Jan; 6(260):ra7. PubMed ID: 23362240
[TBL] [Abstract][Full Text] [Related]
6. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
7. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S
Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313
[TBL] [Abstract][Full Text] [Related]
8. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
9. Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
Wagenaar TR; Ma L; Roscoe B; Park SM; Bolon DN; Green MR
Pigment Cell Melanoma Res; 2014 Jan; 27(1):124-33. PubMed ID: 24112705
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome.
Saridaki Z; Tzardi M; Sfakianaki M; Papadaki C; Voutsina A; Kalykaki A; Messaritakis I; Mpananis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
PLoS One; 2013; 8(12):e84604. PubMed ID: 24367680
[TBL] [Abstract][Full Text] [Related]
11. The role of BRAF V600 mutation in melanoma.
Ascierto PA; Kirkwood JM; Grob JJ; Simeone E; Grimaldi AM; Maio M; Palmieri G; Testori A; Marincola FM; Mozzillo N
J Transl Med; 2012 Jul; 10():85. PubMed ID: 22554099
[TBL] [Abstract][Full Text] [Related]
12. BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib.
Nagasawa I; Kunimasa K; Tsukahara S; Tomida A
Biochem Biophys Res Commun; 2017 Jan; 482(4):1491-1497. PubMed ID: 27965097
[TBL] [Abstract][Full Text] [Related]
13. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype.
Hanly EK; Rajoria S; Darzynkiewicz Z; Zhao H; Suriano R; Tuli N; George AL; Bednarczyk R; Shin EJ; Geliebter J; Tiwari RK
BMC Res Notes; 2014 Mar; 7():187. PubMed ID: 24673746
[TBL] [Abstract][Full Text] [Related]
14. [Progress of anti-tumor study based on BRAF].
Yan GR; Xu ZJ; Wang HY; Zhu WL
Yao Xue Xue Bao; 2012 Dec; 47(12):1567-74. PubMed ID: 23460959
[TBL] [Abstract][Full Text] [Related]
15. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
17. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
18. Effect of BRAF/MEK Inhibition on Epithelioid Glioblastoma with BRAFV600E Mutation: a Case Report and Review of the Literature.
Li Y; Yang S; Hao C; Chen J; Li S; Kang Z; Kang X; Zhang H; Li W
Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776753
[TBL] [Abstract][Full Text] [Related]
19. ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
Peng U; Wang Z; Pei S; Ou Y; Hu P; Liu W; Song J
Oncol Rep; 2017 Feb; 37(2):1270-1276. PubMed ID: 28035401
[TBL] [Abstract][Full Text] [Related]
20. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
Run L; Wang L; Nong X; Li N; Huang X; Xiao Y
Endocrine; 2021 Feb; 71(2):418-426. PubMed ID: 32666385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]